MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5415/apallergy.0000000000000221

Медицинская библиотека · Asia Pacific allergy · 2025

Efficacy and safety of xyloglucan nasal spray in children with allergic rhinitis: A randomized, double-blind, placebo-controlled, crossover study.

Laopakorn Piyapong, Kiewngam Potjanee, Jotikasthira Wanlapa, Sawatchai Adithep, Kanchongkittiphon Wacharoot, Manuyakorn Wiparat

СтатьяПеревод в очереди

Аннотация

BACKGROUND

A tamarind seed extract-based solution containing xyloglucan forms a protective layer over the nasal epithelium. However, there is no previous study evaluating xyloglucan efficacy in children with allergic rhinitis (AR).

OBJECTIVE

To evaluate the safety and efficacy of xyloglucan as an adjunctive treatment for AR in children.

METHODS

This randomized, double-blind, placebo-controlled crossover study assessed the efficacy of xyloglucan nasal spray in managing AR symptoms in children. Participants 6-18 years with AR were randomized to receive either xyloglucan or placebo in addition to their current AR therapy for 2 weeks, followed by a 2-week washout and crossover to the alternate treatment for 2 weeks. Primary outcomes were changes in visual analog scale scores analyzed using linear mixed models, adjusting for treatment, period, sequence, and compliance. Subgroup analyses included children with moderate symptoms and good compliance.

RESULTS

Seventy-nine children with AR were enrolled, median age 10 years (IQR: 8-12). Treatment with xyloglucan was associated with a significantly greater reduction in nasal congestion compared to placebo (β = -1.013, 95% confidence interval [CI], -1.729 to -0.298, P = 0.006). In children with moderate symptoms and good compliance, the effect on nasal congestion was more pronounced (β = -1.588, P = 0.046). Improvements in rhinorrhea, sneezing, and itching were observed but did not reach statistical significance. Both treatments were well tolerated, with only mild adverse events in both groups.

CONCLUSION

Xyloglucan nasal spray, as an adjunct to standard AR treatment, demonstrated potential benefits in alleviating rhinitis symptoms, particularly nasal congestion, in children with AR. This clinical trial was registered with the Thai Clinical Trials Registry (No. TCTR20240318004).

Для цитирования: Laopakorn Piyapong, Kiewngam Potjanee, Jotikasthira Wanlapa, Sawatchai Adithep, Kanchongkittiphon Wacharoot, Manuyakorn Wiparat. Efficacy and safety of xyloglucan nasal spray in children with allergic rhinitis: A randomized, double-blind, placebo-controlled, crossover study.. Asia Pacific allergy. 2025. DOI: 10.5415/apallergy.0000000000000221.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.